Suppr超能文献

唾液皮质醇地塞米松抑制试验在不同精神疾病诊断中的特异性

Specificity of the salivary cortisol dexamethasone suppression test across psychiatric diagnoses.

作者信息

Copolov D L, Rubin R T, Stuart G W, Poland R E, Mander A J, Sashidharan S P, Whitehouse A M, Blackburn I M, Freeman C P, Blackwood D H

机构信息

MRC Brain Metabolism Unit, University Department of Pharmacology, Scotland.

出版信息

Biol Psychiatry. 1989 Apr 1;25(7):879-93. doi: 10.1016/0006-3223(89)90268-0.

Abstract

One hundred forty-eight psychiatric inpatients, 12 outpatients, and 17 normal controls were given the 1.0-mg overnight Dexamethasone Suppression Test (DST), with salivary cortisol concentrations being measured as the dependent variable. Based on the Structured Clinical Interview for DSM-III, the patients were diagnosed as having major depression with melancholia (n = 21), nonmelancholic major depression (n = 50), mania (n = 15), schizophrenia (n = 32), dementia (n = 6), substance dependence/abuse n = 18), and miscellaneous (n = 18). Neither the melancholic major depressives nor the entire group of major depressives had significantly higher salivary cortisol pre- or postdexamethasone as compared with all the other patients combined, nor did the melancholic patients have significantly higher cortisol than the nonmelancholic depressives. The inpatients as a group had significantly higher pre- and postdexamethasone cortisol values than the normal controls; cortisol values for the outpatients were intermediate between these two groups. Illness severity (in the depressives), length of time in hospital before the DST, and medication regimen were all unrelated to DST outcome. Thus, in this study, the salivary cortisol DST showed little clinical utility in discriminating major depressives with and without melancholia from other patients with a broad range of psychiatric diagnoses. The test did distinguish between hospitalized psychiatric patients and normal control subjects and between depressed inpatients and depressed outpatients, indicating that hospitalization-related variables contributed to DST outcome.

摘要

148名精神科住院患者、12名门诊患者和17名正常对照者接受了1.0毫克的夜间地塞米松抑制试验(DST),唾液皮质醇浓度作为因变量进行测量。根据针对《精神疾病诊断与统计手册第三版》的结构化临床访谈,患者被诊断为伴有 melancholia 的重度抑郁症(n = 21)、非 melancholic 重度抑郁症(n = 50)、躁狂症(n = 15)、精神分裂症(n = 32)、痴呆症(n = 6)、物质依赖/滥用(n = 18)以及其他(n = 18)。与所有其他患者合并组相比,伴有 melancholia 的重度抑郁症患者和整个重度抑郁症患者组在服用地塞米松前后的唾液皮质醇水平均无显著升高,伴有 melancholia 的患者的皮质醇水平也没有显著高于非 melancholic 抑郁症患者。住院患者组作为一个整体,服用地塞米松前后的皮质醇值显著高于正常对照组;门诊患者的皮质醇值介于这两组之间。疾病严重程度(在抑郁症患者中)、DST 前的住院时间以及用药方案均与 DST 结果无关。因此,在本研究中,唾液皮质醇 DST 在区分伴有和不伴有 melancholia 的重度抑郁症患者与其他具有广泛精神科诊断的患者方面几乎没有临床实用性。该测试确实区分了住院精神科患者和正常对照受试者以及抑郁住院患者和抑郁门诊患者,表明与住院相关的变量影响了 DST 结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验